Chemical Properties:
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement. Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.Supply Sitagliptin Phosphate Monohydrate Related Intermediates: Sitagliptin API CAS 486460-32-6 Sitagliptin Phosphate Monohydrate API CAS 654671-77-9 2,4,5-Trifluorophenylacetic Acid CAS 209995-38-0 Boc-(R)-3-Amino-4-(2,4,5-Trifluoro-Phenyl)-Butyric Acid CAS 486460-00-8 Sitagliptin Triazole Hydrochloride CAS 762240-92-6 Sitagliptin Phosphate Monohydrate Intermediate CAS 486460-21-3| Item | Specifications |
| Appearance | White to Off-White Powder |
| Identification by HPLC | The Retention Time of Sample is Concordant With Reference Standard |
| Loss on Drying | ≤0.50% |
| Sulphated Ash | ≤0.50% |
| Heavy Metals | <20ppm |
| Isomer | ≤0.50% |
| Related Substances | |
| Impurity A | ≤0.50% |
| Any Other Single Impurity | ≤0.50% |
| Total Impurities | ≤0.50% |
| Purity | ≥99.5% (HPLC) |
| Test Standard | Enterprise Standard |
| Usage | Intermediate of Sitagliptin Phosphate Monohydrate (CAS: 654671-77-9) |
Description:
Specifications:
Package & Storage:
| Chemical Name | Boc-(R)-3-Amino-4-(2,4,5-Trifluoro-Phenyl)-Butyric Acid |
| Synonyms | (R)-Sitagliptin N-Boc-Acid Impurity |
| CAS Number | 486460-00-8 |
| CAT Number | RF-PI1192 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C15H18F3NO4 |
| Molecular Weight | 333.31 |
| Melting Point | 136.0~138.0℃ |
| Brand | Ruifu Chemical |
Advantages:
FAQ:
Application:
Boc-(R)-3-Amino-4-(2,4,5-Trifluoro-Phenyl)-Butyric Acid (CAS: 486460-00-8) is an important intermediate for the preparation of sitagliptin. Sitagliptinphosphate is the first dipeptidase -IV(DPP-4) inhibitor approved by FDA in 2006. It is used for the treatment of type II diabetes mellitus. It has obvious hypoglycemic effect when used alone or in combination with metformin and pioglitazone, and it is safe to take, well tolerated, with few adverse reactions. In August 2009, the drug was approved by the European Union as a first-line drug for the treatment of type 2 diabetes. After 2011, one after another countries have approved the combination of sitagliptin phosphate and alpha glycosidase inhibitors or insulin. Sitagliptin phosphate is the first FDA-approved dipeptidyl peptidase-IV inhibitor to be used in the treatment of type 2 diabetes by far, under the trade name Januvia.
